The latest trading session saw AbbVie (ABBV) ending at $211.48, denoting a +1.17% adjustment from its last day's close. This change outpaced the S&P 500's 1.76% loss on the day. At the same time, the ...

Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with ...

Growth and income investors who want to stay invested but shift to a more balanced approach may want to look at the Dividend ...

AbbVie (ABBV) is entering into the weight-loss space after partnering with Gubra through a licensing agreement. Market Domination's Julie Hyman and Josh Lipton break down this possible alternative to ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

Over the weekend, a Texas aerospace company made history with the first successful landing on the moon by a private firm.

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

AbbVie and Gubra have partnered to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.

As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...